Clinuvel Pharmaceuticals

Clinuvel extended its profit streak, posting the tenth profitable year in a row; revenue exceeded AUD 100m for the second consecutive year, gross margin was 83% and cash and equivalents rose to AUD 252m. Despite strong fundamentals, the stock fell 12.35% pre-market after weakness in US sales of SCENESSE due to competing samples and the announced planned relocation of the headquarters and delisting from the ASX in favor of a Nasdaq listing. The company remains debt-free, continues to invest in R&D and expects ongoing annual spending of around AUD 55m in coming years, while key development programs (vitiligo, NEURACTHEL) still require trials and regulatory decisions. » More on de.investing.com

Clinuvel reports a 4% rise in revenue for H1 FY2026 to A$36.93m — the strongest first half in the company's history — while net profit fell 26% to A$10.4m due to a 22% increase in expansion costs. Operating expenses rose particularly in personnel, clinical development and sales, while cash reserves of A$233m enable a self-funded expansion. Key catalysts are regulatory decisions, first topline results from the vitiligo Phase‑III study CUV105 in H2 2026 and completion of the R&D centre in Singapore; the vitiligo programme represents the largest growth opportunity. » More on de.investing.com